Impact startupHealthSeries C+
Loyal
Loyal is a clinical-stage animal health company developing lifespan extension drugs for dogs. It has raised over $250M, including a $100M Series C in February 2026. It is making progress toward approval from the FDA's Center for Veterinary Medicine.
Founder and CEO
Raised in the rounds listed
$100 million
Founder
Celine Halioua
Founded
2019
Who it reaches
Dog owners and veterinarians, with drugs meant to help dogs live longer, healthier lives.
Loyal funding rounds
| Date | Round | Amount |
|---|---|---|
| Feb 11, 2026 | Series C | $100 million |
Key facts
- Founded
- late 2019source
- Total raised
- over $250Msource
- Series C
- $100M, led by age1, February 11, 2026source
- Drugs in development
- three drugs in developmentsource
- Regulatory status
- making progress toward approval from the FDA's Center for Veterinary Medicinesource
- Study length
- now about two and a half years in, will run a minimum of four yearssource
WYDE coverage of Loyal
Sources
Track the institutions that move money.
Data-driven coverage every Friday.